Engineering TET2-deficient beta cells that resist autoimmune attack to create replacement cell therapies for type 1 diabetes.
Developing an IFNγ-based molecular microscope to assess celiac disease activity and response to treatment without relying solely on diagnostic biopsies.
Using the RIP-NINJA mouse model to study how PD-1 regulation in the pancreas prevents autoimmune induction and checkpoint therapy-induced diabetes.
Using DIPS, a non-invasive skin sampling technique, to build cytokine-based biomarker panels that predict biologic treatment response in psoriasis and atopic dermatitis.
Using wearable sensors and machine learning to analyze real-world movement and sleep data, this project aims to predict treatment response earlier and enable more personalized care for inflammatory arthritis.
Developing a bioavailable DNAseIL3 biologic to degrade pathogenic autoantibodies and treat lupus and related autoimmune diseases.
Investigating how copper transport via SLC31A1 regulates pro-inflammatory Th17 cell activity, this project uncovers a novel link between immune cell metabolism and MS, pointing toward new therapeutic targets.
Identifying the signaling pathways that drive rhinovirus-induced airway inflammation to find small molecule drugs that prevent asthma attacks.
Engineering HLA-DQ–specific CAR Tregs to selectively suppress anti-donor immune responses at sites of graft inflammation, this project seeks a more precise, durable alternative to broad immunosuppression in transplantation.
Restoring thromboangioplasticity in antiphospholipid syndrome by developing recombinant proteins that counteract harmful anti-annexin V antibodies.
